erlotinib hydrochloride has been researched along with d-alpha tocopherol in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (d-alpha tocopherol) | Trials (d-alpha tocopherol) | Recent Studies (post-2010) (d-alpha tocopherol) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 32,198 | 2,903 | 7,258 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | d-alpha tocopherol (IC50) |
|---|---|---|---|
| Glutathione S-transferase P | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bachawal, SV; Sylvester, PW; Wali, VB | 2 |
| Cheng, F; He, B; Luo, K; Meng, G; Peng, X; Pu, Y | 1 |
3 other study(ies) available for erlotinib hydrochloride and d-alpha tocopherol
| Article | Year |
|---|---|
Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Culture Media, Serum-Free; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Mammary Neoplasms, Animal; Mice; Quinazolines; Signal Transduction; Trastuzumab; Vitamin E | 2010 |
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Chromans; Erlotinib Hydrochloride; Female; Gefitinib; Mammary Neoplasms, Animal; Mice; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT Transcription Factors; Vitamin E | 2010 |
Poly(ester-thioether) microspheres co-loaded with erlotinib and α-tocopheryl succinate for combinational therapy of non-small cell lung cancer.
Topics: A549 Cells; alpha-Tocopherol; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Drug Carriers; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Microspheres; Polymers; Porosity; Protein Kinase Inhibitors; Reactive Oxygen Species | 2020 |